Trump Unveils Tariffs Ranging From 25% to 40%
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Cahya Mata Sarawak Berhad's (KLSE:CMSB) top owners are retail investors with 39% stake, while 22% is held by institutions
Cahya Mata Sarawak Berhad's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 9 shareholders Insider ownership in Cahya Mata Sarawak Berhad is 20% This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Every investor in Cahya Mata Sarawak Berhad (KLSE:CMSB) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are retail investors with 39% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Institutions, on the other hand, account for 22% of the company's stockholders. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Let's delve deeper into each type of owner of Cahya Mata Sarawak Berhad, beginning with the chart below. View our latest analysis for Cahya Mata Sarawak Berhad Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Cahya Mata Sarawak Berhad does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Cahya Mata Sarawak Berhad's historic earnings and revenue below, but keep in mind there's always more to the story. Hedge funds don't have many shares in Cahya Mata Sarawak Berhad. Majaharta Sdn Bhd is currently the company's largest shareholder with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 11% and 6.8%, of the shares outstanding, respectively. On further inspection, we found that more than half the company's shares are owned by the top 9 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our most recent data indicates that insiders own a reasonable proportion of Cahya Mata Sarawak Berhad. It has a market capitalization of just RM1.3b, and insiders have RM270m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling. With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Cahya Mata Sarawak Berhad. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Our data indicates that Private Companies hold 18%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. It's always worth thinking about the different groups who own shares in a company. But to understand Cahya Mata Sarawak Berhad better, we need to consider many other factors. Take risks for example - Cahya Mata Sarawak Berhad has 1 warning sign we think you should be aware of. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Trump says Mexico, EU to face 30% tariff from Aug 1
President Donald Trump on Saturday targeted Mexico and the European Union with steep 30 percent tariffs, dramatically raising the stakes in already tense negotiations with two of the largest US trading partners. Both sets of duties would take effect August 1, Trump said in formal letters posted to his Truth Social platform. The president cited Mexico's role in illicit drugs flowing into the United States and a trade imbalance with the EU as meriting the tariff threat. Both partners swiftly slammed the new duties, with the EU warning they could disrupt supply chains -- but insisting it would continue talks seeking an agreement with the US -- while Mexico branded them an "unfair deal." French President Emmanuel Macron expressed "very strong disapproval" of the step and called on the bloc to "resolutely defend European interests." Since returning to the presidency in January, Trump has unleashed sweeping stop-start tariffs on allies and competitors alike, roiling financial markets and raising fears of a global economic downturn. But his administration is coming under pressure to secure deals with trading partners after promising a flurry of agreements. So far, US officials have only unveiled two pacts, with Britain and Vietnam, alongside temporarily lower tit-for-tat duties with China. - 'Not enough' - The fresh duties for Mexico announced by Trump would be higher than the 25 percent levy he imposed on Mexican goods earlier this year, although products entering the United States under the US-Mexico-Canada Agreement (USMCA) are exempted. "Mexico has been helping me secure the border, BUT, what Mexico has done, is not enough," Trump said in his letter to Mexican President Claudia Sheinbaum. "Starting August 1, 2025, we will charge Mexico a Tariff of 30% on Mexican products sent into the United States." The Mexican government said it had been informed of the new threat during talks in the United States on Friday. "We mentioned at the table that it was an unfair deal and that we did not agree," the Mexican economy and foreign ministries said in a joint statement. The EU tariff is also markedly steeper than the 20 percent levy Trump unveiled in April, as negotiations with the bloc continue. "Imposing 30 percent tariffs on EU exports would disrupt essential transatlantic supply chains, to the detriment of businesses, consumers and patients on both sides of the Atlantic," European Commission chief Ursula von der Leyen said in a statement, in reply to Trump's letter to her. "We remain ready to continue working towards an agreement by August 1. At the same time, we will take all necessary steps to safeguard EU interests, including the adoption of proportionate countermeasures if required," she added. Meanwhile Macron backed efforts to reach an agreement that "reflects the respect that trade partners such as the European Union and the United States owe each other." But he urged the bloc to "step up the preparation of credible countermeasures" to implement if the two sides fail to reach an agreement in time. - Precarious moment - The EU, alongside dozens of other economies, had been set to see its US tariff level increase from a baseline of 10 percent on Wednesday, but Trump pushed back the deadline to August 1. Mexico and Canada come under a separate tariff regime. Since the start of the week, Trump has sent out letters to more than 20 countries with updated tariffs for each, including a 35 percent levy for Canada. A US official told AFP Saturday that the USMCA exemption was expected to remain for both Mexico and Canada, although the president has yet to make final decisions. Brussels said Friday that it was ready to strike a deal with Washington to prevent the return of 20 percent levies. The EU has prepared retaliatory duties on US goods worth around 21 billion euros after Trump also slapped separate tariffs on steel and aluminum imports earlier this year, and they are suspended until July 14. European officials have not made any move to extend the suspension but could do it quickly if needed. "Despite all the movement toward a deal, this threat shows the EU is in the same camp of uncertainty as almost every other country in the world," said Josh Lipsky, chair of international economics at the Atlantic Council. He told AFP that the path forward now depends on how the EU responds, calling it "one of the most precarious moments of the trade war so far." bys-st/md/aks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
an hour ago
- CNN
The deadly drug that's complicating US-China trade
Since US President Donald Trump – just days into his second term – began imposing tariffs on China for its role in the flow of deadly opioids like fentanyl into the United States, Beijing's message has been clear. The fentanyl crisis is the 'US's problem,' Chinese officials have repeatedly said, and China has already done 'tremendous work' to address the issue. 'We stand ready for practical cooperation with the US based on equality and mutual respect. That said, we firmly oppose the US pressuring, threatening and blackmailing China under the pretext of the fentanyl issue,' a spokesperson said in March, after Trump's fentanyl tariffs were raised to 20% on all Chinese imports into the US. But as those tariffs remain in place months later and, despite a truce de-escalating other duties, Beijing is signaling it's paying attention to the issue – and may be prepared to do more. China late last month announced it will add two more fentanyl precursors to its list of controlled substances – an expected step that brought it in line with international regulations, which its diplomats presented as a mark of 'active participation' in global drug control. Days earlier, Chinese authorities also extended control over another class of drug known as nitazenes – powerful synthetic opioids raising alarm among global health officials. The same day, Chinese Minister of Public Security Wang Xiaohong told US Ambassador to China David Perdue that Beijing was open to strengthening 'practical cooperation' on drug control. The Trump administration blames China for 'sustaining' the influx into the US of fentanyl, a lab-made, synthetic opioid dozens of times more potent than heroin. Abuse of the drug and its analogues has fueled a drug overdose crisis in the US, killing tens of thousands of Americans annually, though those numbers saw a significant drop last year. In Beijing's view, it's gone above and beyond international norms to stem the outflow of the drug and its component chemicals from its vast pharmaceuticals sector. In 2019 Beijing controlled fentanyl as a drug class – a significant move that drastically reduced the flow of the finished drug directly from China to the US, according to experts and US officials. It didn't take long for criminal networks to adapt, however. Chinese outfits shifted to selling precursor chemicals often to cartel-backed labs in Mexico, which then make and ship illegal fentanyl and similar drugs to the US. Chinese authorities have since controlled a number of these precursor chemicals. But experts and US officials say more could be done – as Beijing remains the largest source for products used to make illegal fentanyl and other synthetic drugs in Mexico and other countries. Chinese officials haven't explicitly linked their recent efforts at controlling two more of these substances to relations with the US, instead calling them another example of the 'goodwill China has shown,' and continuing to reject the premise of the US tariffs. But Beijing is likely expecting it will get credit for the latest moves in trade negotiations with the US. The question, however, is whether the steps will move the needle for Washington – and whether the two sides will be able to cooperate on the issue if their overall relations remain rocky. 'If Washington does not publicly recognize Chinese steps and show responsiveness to Beijing's own concerns, then bilateral law enforcement cooperation likely will falter going forward,' said Ryan Hass, director of the John L. Thornton China Center at the Brookings Institution. As US-China ties have chafed on everything from technology to China's militarization of the South China Sea, few issues have appeared more personal to American leaders than China's role as a producer of the drugs and chemicals fueling an opioid crisis in the US. During his first term, Trump hailed Chinese leader Xi Jinping's 'wonderful humanitarian gesture' of designating fentanyl a controlled substance in China. Some six years later, however, Trump began his second term accusing China of 'actively sustaining and expanding the business of poisoning our citizens' – an accusation vehemently denied by China. That message also contrasts with assessments from the US Drug Enforcement Agency which, in an annual report released in May, said fentanyl purity declined throughout 2024, consistent with indications that fentanyl cooks in Mexico were having trouble obtaining key precursor chemicals. That was as some China-based suppliers were 'wary of supplying controlled precursors … demonstrating an awareness on their part that the Chinese government is controlling more fentanyl precursors,' it said. Beijing's latest moves to control the two additional fentanyl precursors and nitazenes are positive actions that could have an impact on illicit drug supply chains, experts say. But they are also 'clever maneuvering' from China, according to Vanda Felbab-Brown, a senior fellow at the Strobe Talbott Center for Security, Strategy, and Technology at the Brookings Institution. A UN convention on illicit drugs added the two fentanyl precursors to its list of controlled substances last year, meaning signatory countries such as China must follow suit. China controlled a number of nitazenes in 2024 and the latest step, which expands those controls, was already in the works last fall, Felbab-Brown said. 'The Trump administration just reset the clock, did not recognize what China had already done and had committed to do, did not give China any credit for that. As a result, it also now is in a position where China can be promising to do exactly the same actions that it had promised to the Biden administration and use that as part of the bargaining,' Felbab-Brown said. A 'more effective posture' would have been to embrace China's efforts in 2024 and then ask it to fill in the 'substantial and impactful' holes in its drug control program, she added. Beijing has fiercely defended its record when it comes to controlling fentanyl and other synthetic drugs, releasing a 7,000-word white paper outlining its efforts in March, days after Trump imposed his second raft of fentanyl-linked tariffs. It has also balked at a Congressional report released last year accusing the ruling Chinese Communist Party of directly subsidizing the manufacture and export of illicit fentanyl materials and other synthetic narcotics through tax rebates. In China, where the Communist Party keeps a tight grip on all aspects of society, there's comparatively limited opioid abuse, according to official data – a situation Beijing uses to suggest the problem is about American appetite for the drug, not Chinese supply. That also means Chinese officials feel they've gone out of their way to work with Washington on a US domestic issue – efforts they see as being greeted first by a lack of American appreciation, and then by tariffs. Scientists in China on the front lines of identifying new precursors being used by criminal groups also point to reducing demand in the US as a key factor, given the challenges of controlling chemicals involved in synthesizing opioids. 'You really can't solve the fentanyl problem through control alone… the most fundamental issue is still reducing demand,' Hua Zhendong, deputy director of a drug analysis division at a counternarcotics laboratory under China's Ministry of Public Security, told CNN in an interview last September. He pointed to how some chemicals have widespread use in legitimate products, making them impractical to control, while chemicals used to make fentanyl can be easily adjusted to evade rules but still produce the product. 'It's always been like a cat-and-mouse game, because there could be thousands of potential substances for synthesizing fentanyl, we can't proactively control them all – we can only passively follow behind,' said Hua, whose lab was working regularly with US counterparts at the time of the interview to share information on emerging chemicals. Outside observers agree that US efforts to curb demand are critical for mitigating the opioid crisis. They note too that even if no chemicals came from China, fentanyl makers would look to other countries with large pharmaceuticals and chemicals industries, such as India. Despite the challenges of enforcement in a vast sector where goods are often shipped in covert ways by busy air and sea routes, observers also say that more can be done in China. That includes tightening regulations to enable tougher punishments for people who sell controlled precursors to criminal groups or their middlemen unknowingly. Experts also say more could also be done to enforce existing regulations, especially in terms of how central government edicts are enforced by local authorities across China. 'Scheduling drugs and precursors that lead to the production of illegal drugs is one step of many needed in China,' said David Luckey, a senior international and defense researcher at RAND, a US-based think tank. 'I would suggest better still would be actually preventing Chinese companies from selling and distributing these harmful chemicals and drugs to criminal organizations in Mexico.' In addition to China, Trump placed tariffs on Mexico and Canada earlier this year, accusing them of not doing enough to curb migration and fentanyl trafficking, but carved out significant exemptions to those tariff rates. The US earlier this year designated Mexican cartels it alleges are involved in fentanyl trafficking as foreign terrorist organizations. 'China is a command economy with extreme control of its population – I think if the Chinese Communist Party didn't want Chinese companies doing this, the CCP could do more to stop it, and be more effective in stopping it,' Luckey said. An annual US State Department report on narcotics controls released in March described China's 'significant steps' working with the US last year to reduce precursor exports, which it said included cracking down on online platforms and companies selling them, making arrests, and adding 55 synthetic drugs and precursor chemicals to control lists. China's Ministry of Public Security last month said it had seized more than 1,400 tons of various precursor chemicals, and 151 related criminal cases were resolved in 2024. But authorities in China also acknowledge the scope of the problem, with a recent report noting that channels and means for smuggling chemicals out of the country 'were increasing' and 'constantly being updated,' creating 'greater challenges.' Beijing – which seeks to present itself as a responsible global player – has its own reasons for not wanting to be seen as an international purveyor of illicit drugs. But Chinese officials have long linked cooperation with the US on the issue to the health of the broader relationship. China cut off drug control cooperation completely in August 2022 in retaliation for then House Speaker Nancy Pelosi's visit to Taiwan. It then took a friendly summit between Xi and former US President Joe Biden in late 2023 to get collaboration back on track. This time around, China has bristled at the Trump administration's off-the-bat imposition of tariffs, saying it 'undermines' cooperation. The White House did not respond to a CNN request for comment on China's latest control steps. 'If the US truly wants to cooperate with China, it should face up to the objective facts, correct its wrongdoing, and seek dialogue with China,' a Chinese foreign ministry spokesperson said last month when asked whether those measures were done in cooperation with the US or at its behest. But Beijing is also keenly aware that the current tariffs are hitting at a time when China's economy has already been struggling with domestic challenges – and there's no certainty those duties couldn't rise again under Trump's capricious trade policy. 'Since the 20% tariff is specifically linked to cooperation on fentanyl, the Chinese might be hoping for a package deal that includes trade, counternarcotics, among other things,' said Yun Sun, director of the China program at the Stimson Center think tank in Washington. 'The Chinese hope to remove the 20% tariff … (and are) eager to get President Trump to visit China this year, so they need to work out good progress,' she said.
